← Browse by Condition
Medical Condition

sarcopenia in liver cirrhosis

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for sarcopenia in liver cirrhosis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — sarcopenia in liver cirrhosis Clinical Trials

How many clinical trials are currently recruiting for sarcopenia in liver cirrhosis?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for sarcopenia in liver cirrhosis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for sarcopenia in liver cirrhosis?
sarcopenia in liver cirrhosis research spans Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a sarcopenia in liver cirrhosis clinical trial?
Eligibility criteria for sarcopenia in liver cirrhosis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
1
Top Sponsors
Mattias Ekstedt 1 trial
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies 1 trial

Recruiting Clinical Trials

NCT07291141
Recruiting
A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis
Enrollment
600 pts
Location
Sweden
Sponsor
Mattias Ekstedt
View Trial →
NCT06814626 Phase 3
Recruiting
Role of Nutritional Intervention for the Treatment of Sarcopenia in Cirrhotic Patients with Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome
Enrollment
72 pts
Location
Italy, Switzerland
Sponsor
The Mediterranean Institute fo...
View Trial →

Related Conditions

liver cirrhoses (1) hepatocellular carcinoma hcc (1) portal hypertension related to cirrhosis (1) mri (1) ultrasound (1) liver cirrhosis (1) refractory ascites in patients with cirrhosis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology